Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italia.
Int Arch Allergy Immunol. 2010;152(4):384-9. doi: 10.1159/000292947. Epub 2010 Mar 4.
Chronic urticaria (CU) patients often present activation of the coagulation cascade and fibrinolysis whose markers correlate with disease severity.
We evaluated whether CU patients with elevated plasma D-dimer have a poor response to antihistamines, and anticoagulation and inhibition of fibrinolysis may be beneficial in these patients.
Sixty-eight consecutive patients with CU were prescribed cetirizine 10 mg daily for 2 weeks; plasma D-dimer was measured. Non-responders were given cetirizine 30 mg daily for 1 week and subsequently, in case of failure, systemic steroids. Patients with persistent uncontrolled CU and elevated D-dimer plasma levels were offered subcutaneous nadroparin 11,400 IU once a day and oral tranexamic acid 1 g three times a day for 2 weeks.
D-dimer levels were elevated in 14/68 (20.6%) patients (range 306-7,317 ng/ml; normal values <278 ng/ml) and were associated with a more severe disease. Twelve of 14 patients with elevated D-dimer levels did not respond to antihistamine treatment (p = 0.0001). On the whole, 14 patients reported a poor or absent response to cetirizine 10 mg daily and only 1 of these responded satisfactorily to cetirizine 30 mg daily. Eight patients with elevated D-dimer and whose disease was not satisfactorily controlled by prednisone received nadroparin and tranexamic acid. A marked improvement of symptoms was observed in 5/8 cases.
Our findings indicate that CU patients with elevated D-dimer often present a more severe disease with reduced response to antihistamines. Based on this short pilot study, some of these patients may benefit from treatment with nadroparin and tranexamic acid.
慢性荨麻疹(CU)患者常出现凝血级联和纤维蛋白溶解的激活,其标志物与疾病严重程度相关。
我们评估了血浆 D-二聚体升高的 CU 患者是否对抗组胺药物反应不佳,抗凝和抑制纤维蛋白溶解是否对这些患者有益。
68 例连续 CU 患者每天服用西替利嗪 10mg,共 2 周;测量血浆 D-二聚体。非应答者每天服用西替利嗪 30mg,持续 1 周,如果失败,给予全身皮质类固醇。对于持续无法控制且血浆 D-二聚体水平升高的 CU 患者,给予每天皮下给予那屈肝素 11400IU 和每天口服氨甲环酸 1g,共 2 周。
14/68(20.6%)患者的 D-二聚体水平升高(范围 306-7317ng/ml;正常值<278ng/ml),且与疾病更严重相关。14 例 D-二聚体升高的患者中有 12 例对抗组胺治疗无反应(p=0.0001)。总的来说,14 例患者每天服用 10mg 西替利嗪的反应差或无反应,只有 1 例对每天 30mg 西替利嗪有满意的反应。8 例 D-二聚体升高且泼尼松治疗控制不佳的患者接受了那屈肝素和氨甲环酸治疗。5/8 例患者的症状明显改善。
我们的研究结果表明,D-二聚体升高的 CU 患者常表现为更严重的疾病,对抗组胺药物的反应降低。基于这项短期初步研究,其中一些患者可能受益于那屈肝素和氨甲环酸治疗。